StoryTest
COMMAND early feasibility study meets primary safety endpoint
Synchron reported positive results from its COMMAND early feasibility study of the Stentrode endovascular brain-computer interface. All six participants with severe paralysis met the primary safety endpoint of no device-related serious adverse events causing death or permanent disability over the 12-month follow-up. Brain signals corresponding to motor intent were reliably captured and converted to digital motor outputs throughout the year.
- Primary endpoint met: no device-related serious adverse events (SAEs) affecting brain or vasculature in any of six participants over 12 months post-implant.
- Study sites: Mount Sinai, Gates Vascular Institute (Buffalo), and UPMC; results presented at Congress of Neurological Surgeons meeting September 2024.
- Stentrode placed via minimally invasive endovascular procedure through blood vessel; demonstrates sustained safety and consistent neural signal capture over extended follow-up.